Both physiological and pharmacological levels of the pineal hormone melatonin exhibit substantial anticancer activity in tissue-isolated rat hepatoma 7288CTC via melatonin receptor-mediated blockade of tumor uptake of linoleic acid (LA) and its metabolism to the mitogenic signaling molecule 13-hydroxyoctadecadienoic acid (13-HODE).
Introduction
Many environmental factors influence the development and growth of cancer and it is known that diet exerts a major impact on all stages of oncogenesis. Several nutritional and epidemiological studies indicate that consuming diets rich in vegetables and fruits may help reduce the incidence of a broad range of malignancies (1, 2) . In this regard, plant foods provide a high level of antioxidant nutrients such as vitamins C, E and beta carotene. They also contain other phytochemicals with estrogenic or anti-estrogenic activity such as flavones, isoflavones, polyphenols, chalcones and indoleamines (3) . With respect to plant-derived indoleamines, indole-3-carbinol (I3C) is a major glucoinolate found in cruciferous vegetables such as Brussels sprouts, cabbage, broccoli and cauliflower (4) . I3C has been shown to inhibit rodent mammary carcinogensis in vivo (5), human breast cancer growth in vitro via anti-estrogenic mechanisms (6) , and human prostate cancer cell growth in vitro via antiepidermal growth factor (EGF)-related mechanisms (7) .
Melatonin (N-acetyl, 5-methoxytryptamine) is a chronobiotic, indoleamine neurohormone produced by the pineal gland during darkness in mammals, including humans (8) . At both physiological and pharmacological blood concentrations, melatonin plays an important role in a number of physiological and pathophysiological processes including circadian rhythm regulation, sleep disturbances, seasonal reproduction, retinal physiology, immune function, intermediary metabolism (9) and tumorigenesis (10, 11) . Melatonin's mechanism of action in the regulation of many of these processes is thought to involve inhibitory G protein-coupled melatonin receptors (MT 1 and MT 2 ) leading to the suppression of cAMP production, and a modulation in the activity of related signaling pathways as well (12) . Melatonin is also a highly efficient and potent free radical scavenger/antioxidant molecule. Physiological blood levels of this indole are tightly correlated with the total antioxidant capacity of the serum (13, 14) .
In addition to its endogenous production by the pineal gland in vertebrate species, significant quantities of melatonin have been detected in all major non-metazoan taxa studied including bacteria, dinoflagellates, euglenoids, trypanosomids, fungi, rhodophyceans, pheophyceans, chlorophysceans and angiosperms (15) . Among angiosperms, melatonin is found in a number of species of fruits, vegetables and medicinal plants consumed by animals and humans. Melatonin is present in edible plants in concentrations that are several orders of magnitude higher than nocturnal blood concentrations produced by the pineal gland and it is found in all plant parts including roots, stems, leaves, fruit and seeds (15EE22). Additionally, the consumption of melatonin-rich food acutely elevates immunoreactive (IR) and bioactive blood melatonin levels in chickens (17) .
A more abundant source of exogenous melatonin in the human diet comes from commercially available nutritional supplements regularly consumed by millions of people throughout the world most often for sleep problems and/or jet lag (23, 24) . These supplements contain anywhere from 250 mg to 5 mg of melatonin delivered in either gel-cap or tablet form (24) . In humans, the absolute oral bioavailability of milligram doses of oral melatonin from nutritional supplements is~15% (25) whereas the oral bioavailability of microgram doses varies from 10 to 56%, presumably due to variations in first-pass hepatic metabolism (26) . Nevertheless, the oral ingestion of microgram amounts of melatonin results in near physiological nocturnal blood levels of melatonin (27) . In comparison, nutritional supplements containing milligram amounts of melatonin can produce peak circulating melatonin levels that are 10EE100 times greater than the normal peak produced by the pineal gland during darkness (25) . Although the absolute bioavailability of a 300 mg oral dose of melatonin in male rats was reported to be 53% (28) , the absolute oral bioavailability and physiological effects of melatonin derived from foodstuffs is unknown for any animal species (18) . However, it is important to note that the dietary intake of pharmacological amounts of either melatonin or melatonin agonists influences the phase-shifting response of the central circadian timing system in rodent species (29, 30) .
Numerous studies have demonstrated that physiological and pharmacological blood concentrations of melatonin inhibit tumorigenesis in a variety of in vivo and in vitro experimental models of neoplasia (10, 11, 31, 32) . Several clinical cancer trials have demonstrated melatonin's efficacy as a single therapeutic agent, and its ability to raise the therapeutic index when used in conjunction with standard anticancer treatments (31, 33EE35) . We demonstrated recently that a major mechanism by which physiological and pharmacological blood levels of melatonin inhibits cancer growth (i.e. rat hepatoma 7288CTC) is via a melatonin receptor-mediated suppression of tumor linoleic acid (LA) uptake and its metabolism to 13-hydroxyoctadecadienoic acid (13-HODE) (36, 37) . LA, an n-6 polyunsaturated essential fatty acid (FA), is consumed at high levels in the western diet (38EE42), and is a potent promoter of experimental murine and human tumor growth (43, 44) . As the mitogenic signal for LAdependent tumor growth, 13-HODE (43,44) enhances EGFresponsive mitogenesis through EGF receptor autophosphorylation and tyrosine phosphorylation of key downstream signal transduction proteins such as mitogen-activated protein kinases (MEK and ERK1/2) (45, 46) . Therefore, the purpose of this investigation was to: (i) confirm the presence of significant quantities of IR-melatonin in edible plants; (ii) determine, in rats, the plasma and tumor levels of melatonin that may result from the dietary ingestion of quantities of melatonin found in melatonin-rich foods; (iii) determine whether the dietary intake of amounts of melatonin found in melatonin-rich foods leads to a significant inhibition of the growth of tissue-isolated rat hepatoma 7288CTC via melatonin receptor-mediated suppression of tumor LA uptake and 13-HODE production.
Materials and methods

Melatonin levels in edible plants
Only edible plants were selected for the analysis of melatonin concentrations. Whenever possible, the plant food analyzed was fresh and locally grown, otherwise they were purchased from the local food market. In order to compare extraction efficiencies, plant samples were extracted with one of three different solvents. However, since melatonin extraction efficiency with PBS was superior to either methanol or chloroform (data not shown), only methods and results relevant to PBS are detailed. The fruits or vegetables were minced into small sections, and 0.5 g of the sample was weighed into a 50 ml centrifuge tube (Sarstedt, Newton, NC) containing 4 ml of PBS at pH 7.4. A Polytron blender was used to homogenize the samples on ice. The samples were placed in a centrifuge for 15 min at 4 C and spun at 12 100 g. The supernatant was removed and stored at À20 C for later melatonin analysis (47) . Samples were thawed at room temperature and analyzed for melatonin concentrations (see below). Dry weight of the plant specimens was determined by weighing~1 g of wet sample into an aluminum pan in duplicate. The pans were then placed in a 100 C oven for 48 h and the samples were allowed to dry to a constant weight. Plant melatonin concentration is expressed as ng/g dry weight.
Animals, diets and tumor implantation and growth Male Buffalo rats BUF(BUF/Ncr) (NCI) rats (4EE5 weeks old) weighing 35EE75 g and used in tumor growth and perfusion studies were purchased from Charles River Laboratories, Kingston, NY. Male SpragueEEDawley rats (Hsd: SpragueEEDawley Ò SD Ò ) weighing 150EE200 g, that were used as blood donors for the tumor perfusion experiments, were purchased from Harlan SpragueEE Dawley, Indianapolis, IN. Buffalo rats were given free access to water and a semi-purified diet containing 5 or 10% corn oil to provide a fixed amount of LA. Diets were prepared weekly and contained 0.5 g BHT/1500 g diet and were stored in sealed plastic bags at À20 C. Rats were housed two per cage and obtained their food from wide-mouthed glass feeding jars. SpragueEE Dawley blood donor rats were housed two per cage and given free access to water and a standard laboratory diet (Prolab mouse, rat and hamster 1000 formula; Agway, Syracuse, NY). All rats were subjected to alternate 12-h periods of dark and light (lights on from 06:00 to 18:00 h) in a facility with animal care and use programs accredited by AAALAC International, and in accordance with the Guide for the Care and Use of Laboratory Animals. There was no light contamination in the animal rooms during the dark phase (48) , and the temperature and humidity were maintained at 23 C and 40EE60%, respectively. Procedures for implantation of tissue-isolated Morris hepatoma 7288CTC in male Buffalo rats have been described in detail in previous reports (38EE44). Briefly, a 3 mm cube of tumors was sutured to the tip of a vascular stalk formed from the superficial epigastric artery and vein. The tumor implant and vascular stalk were enclosed within a parafilm envelope, placed in the inguinal fossa and the skin incision closed. Vascularization of the implant was limited to new vessel connections with the epigastric artery and vein; subsequent tumor growth was subcutaneous. The latency period (i.e. time to first palpable, peasized mass) was determined for each animal in each experiment. When tumors reached sufficient size for measurement, rats were subjected to light CO 2 -narcosis, and tumor dimensions were measured through the skin with vernier calipers and were then converted to tumor weights using a linear regression formula as described previously (39) . Growth rates (g/day) were generated by linear regression analysis from the estimated tumor weights for the treated and control animals during the course of the study. The final tumor weight was determined by weighing at the end of the experiment.
Steady-state plasma levels of melatonin pinealectomized rats following dietary melatonin intake Surgical pinealectomy was performed under nembutal anesthesia (Abbot Labs., N.Chicago, IL) (50 mg/kg i.p.) as described previously (49) . Pinealectomized male Buffalo rats were fed a semi-purified diet containing 10% corn oil to which synthetic melatonin (Sigma, St Louis, MO) was added so that rats would ingest either 0 ng, 500 ng, 5 mg or 50 mg melatonin/day over a period of 3 weeks. At the end of this period, blood collections (1 ml) were made via cardiac puncture performed on separate groups of animals anesthetized by CO 2 inhalation and sampled every 4 h during a 24-h period as described previously (37, 48) . During the dark phase, blood samples were collected in a completely dark room, with no light leaks, under a dim red-light (Kodak 1A safelight). Plasma samples were then stored frozen at À20 C and later assayed for steadystate melatonin concentrations using a melatonin radioimmunoassay (RIA) (see below).
Tumor growth, FA uptake and metabolism and steady-state plasma melatonin levels in vivo in response to dietary intake of melatonin and/or melatonin receptor antagonist S20928 In tumor growth study #1, pineal-intact male rats were placed on a semipurified 5% corn oil diet. Melatonin was mixed with the diet so that each rat consumed either 0 ng, 500 ng or 5 mg of melatonin/day. In tumor growth study #2, each rat consumed either 0, 50 or 500 ng of melatonin/day or 5 mg/day of melatonin receptor antagonist S20928 (Servier, Courbevoie Cedex, France) either alone or in combination with 500 ng of melatonin/day. The diets in both tumor growth studies commenced 2 weeks prior to tumor implantation and continued thereafter until the end of the experiments. Following tumor implantation, tumor growth measurements were performed every 2 days for up to 7 weeks as described above. At the end of the tumor growth period in each treatment group, when tumors were~4.5EE7.5 g, rats were anesthetized and anticoagulated with sodium heparin. The carotid artery and tumor vein were D.E.Blask et al.
cannulated, and blood samples were collected from each vessel simultaneously during the light phase (08:00 h). Measurements of arteriovenous (A-V) differences for total FAs, LA and 13-HODE were performed and rates of uptake and release were calculated as described previously (41EE44). Two days prior to the termination of tumor growth study #1, blood collections (1 ml) were made via cardiac puncture during a 24-h period as described above. Steady-state plasma melatonin concentrations were measured by RIA as described below.
Effects of perfusion of tissue-isolated hepatoma 7288CTC in situ with different doses of melatonin on FA and LA uptake, 13-HODE release, DNA content and [ 3 H]thymidine incorporation into DNA Tumors weighing~5 g in pineal-intact male Buffalo rats, were perfused in situ as described previously (40) . Virtually melatonin-free arterial blood was collected during the early light phase (08:15EE08:45 h) from pinealectomized donor male SpragueEEDawley rats. Donor blood was contained in a chilled (4 C) reservoir and was pumped to the tumor through a warm water bath (37 C) and an artificial lung as described previously (36, 37) . Upon the establishment of steady-state perfusion conditions, melatonin was added to the perfusate to achieve blood plasma concentrations of either 0, 100, 300 or 600 pM, 1 nM or 1 mM. Following 2 h of perfusion with melatonin, A-V differences for total FAs, LA, 13-HODE, hematocrit, pO 2 , pCO 2 and pH were measured as described previously (36, 37, 41EE44 (36, 40, 43) . Tumor DNA content was measured in 20% (w/w) homogenates fluorometrically using Hoechst dye 33258 using the procedure described in Technical Bulletin #119, Hoefer Scientific Instruments (San Francisco, CA).
Lipid extraction and analyses
Total plasma, tumor and dietary lipids were extracted using the procedure of Folch et al. (50) and analyzed by gas chromatography, as described previously (40, 43, 44) . Extraction of 13-HODE from tumor venous blood and analysis by HPLC were performed as described (40, 43, 44) .
Melatonin analysis
Melatonin analyses were carried out on extracted plant tissue samples, arterial and venous blood plasma samples and tumor tissue samples using a highly sensitive RIA purchased from ALPCO (Windham, NH).
Statistical analysis
Differences among mean latencies to tumor onset, tumor total FA and LA uptake, tumor 13-HODE release, tumor melatonin and FA concentrations and plasma melatonin levels were determined with a one-way ANOVA followed by StudentEENewmanEEKeul's multiple comparisons post hoc test. Differences among the slopes of regression lines between experimental groups and their corresponding control groups were determined by regression analyses and tests for parallelism. Differences were considered to be statistically significant at P 5 0.05.
Materials
Chloroform (HPLC grade), methanol, glacial acetic acid, heptane, hexane and Sep-Pak C18 Cartridges for HPLC sample extraction were purchased from Fisher Chemical (Pittsburgh, PA). Methly esters of rapeseed oil and FA HPLC standards were obtained from Supelco (Bellefonte, PA). Free FA and lactic acid standards, BHT, boron trifluoride-methanol, enzymes, nucleotides and buffers were purchased from Sigma Chemical (St Louis, MO). The HPLC standards, 5-HETE and 13-HODE (each as the racemic mixture) were purchased from Cayman Chemical (Ann Arbor, MI). Dietary ingredients were purchased from US Biochemicals (Cleveland, OH). The melatonin RIA kit was purchased from ALPCO.
Results
IR-melatonin concentrations in edible plants and plant parts
Based on a preliminary screening of levels of IR-melatonin in 41 edible plants and plant-derived foods (data not shown), we determined the plant to plant and within plant melatonin concentrations in a variety of 20 edible plants and plant parts including some of those reported previously to contain significant amounts of melatonin (16EE20,51EE53). In a few cases, melatonin concentrations were assessed in different parts of the same plant. This analysis was performed with three different extraction procedures that utilized either PBS, methanol or chloroform. Since significantly more IR-melatonin/g dry plant tissue was extracted with PBS than with either methanol or chloroform (data not shown), results obtained only with PBS extraction are reported. Table I shows that different amounts of melatonin were extracted from different plants or plant parts. Peanuts, walnuts and mustard seed contained the highest mean IR-melatonin levels (i.e. 41 ng/g) with mustard seed containing the highest amounts (i.e. 1.9 ng/g). The lowest mean quantities of IR-melatonin (i.e. 520 pg/g) were found in grapes. There was considerable variation in IR-melatonin levels between and within plant species.
Effects of dietary melatonin on 24-h steady-state plasma melatonin concentrations in pinealectomized rats
To determine whether the dietary intake of melatonin, in quantities approximating those supplied by edible plants, would raise nocturnal circulating melatonin concentrations Foods were either locally grown or were purchased at a local supermarket. A sample of each plant was removed, freeze-dried and a portion (0.25 g) subsequently extracted with 1Â PBS. The supernatants were analyzed for their melatonin content using an ultrasensitive double antibody RIA kit. Assay sensitivity was 0.3 pg/ml. Values represent the mean AE SD melatonin levels (pg/g dry plant material). Four different samples were analyzed per plant type. Numbers in ( ) represent the range of melatonin values within a given plant type; numbers in { } represent the within plant % coefficient of variation (CV); numbers in [ ]represent the between plant % CV.
Phytomelatonin suppression of rat hepatoma growth into the nocturnal physiological and/or pharmacological ranges in the absence of the endogenous melatonin signal we consulted recommendations by the American Institute for Cancer Research for an`all-plant' diet (3) as well as values of edible plant levels of melatonin obtained from the literature (16EE20,51EE53) and the present study. From this information, an estimate was made that the daily human consumption of à melatonin-rich' plant diet would supply~500 ng of melatonin/day. Therefore, pinealectomized (i.e. no endogenous melatonin signal) non-tumor-bearing rats were provided with a semi-purified diet ad libitum supplemented with melatonin such that rats consumed either 0 ng, 500 ng, 5 mg or 50 mg/day over a 3-week period. Figure 1 shows that the nocturnal plasma melatonin signal was absent in rats receiving either no melatonin supplementation or 500 ng of melatonin/day. However, in animals ingesting 5 mg of melatonin/day, nadir levels of melatonin at 20:00 h progressively increased by 3.5-fold to a physiological peak at 04:00 h followed by a gradual decrease over the next 16 h. In animals ingesting 50 mg of melatonin/ day, circulating melatonin remained consistently at high nocturnal levels (%70EE80 pg/ml) throughout the 24-h period with no rhythm being detected.
Tumor growth study #1: effects of dietary melatonin intake on the growth, LA uptake, and 13-HODE production in hepatoma 7288CTC and steady-state plasma (24-h) and tumor melatonin concentrations in pineal-intact rats In tumor-bearing, pineal-intact rats ingesting the 500 ng melatonin/day diet, the latency to tumor (i.e. palpable tumors) onset (13.3 AE 1.3 days post-implant) was significantly later (P 5 0.05) than in controls (8.0 AE 2.2 days post-implant). The tumor growth rate (0.32 AE 0.02 g/day) in this group was markedly slower than in the control group ingesting a melatonin-free, diet (0.76 AE 0.03 g/day) ( Figure 2 ). In the group ingesting the 5 mg melatonin/day diet, the latency to tumor onset (20.8 AE 2.1 days post-implant) was substantially extended (P 5 0.05) as compared with both the 500 ng melatonin/day and control groups. The tumor growth rate in the 5 mg melatonin/day group (0.18 AE 0.02 g/day) was much slower (P 5 0.05) than that in the 500 ng melatonin/day and control groups ( Figure 2) . A-V difference measurements were performed across tumors at the end of the growth period in each group are shown in Figure 2 . These measurements indicated that tumor LA and total FA uptakes (Table II) , as a percent of supply, were significantly reduced in the 5 mg and 500 ng melatonin/day groups as compared with the control group. In comparison with the 500 ng melatonin/day group, tumor LA and total FA uptakes in the 5 mg melatonin/day group were substantially less (Table II) . Similarly, the tumor concentrations of LA and total FA in the 5 mg/day group were significantly diminished as compared with those in the control group (Table II) . Tumor LA and total FA concentrations in 500 ng melatonin/day group were considerably less than in the controls. Additionally, tumor LA and total FA concentrations were significantly less in the 5 mg melatonin/day group as compared with animals ingesting 500 ng melatonin/day. The dietary intake of 5 mg or 500 ng melatonin/day resulted in tumor 13-HODE release that was markedly less than in the controls (Table II) . Tumor 13-HODE release was also significantly lower in the rats ingesting 5 mg versus 500 ng melatonin/day. Figure 3 shows that a robust nocturnal plasma melatonin signal was present in the tumor-bearing, pineal-intact rat Fig. 1 . Effects of dietary melatonin on mean (AESD) plasma levels of melatonin in tumor-free pinealectomized male rats. Rats were fed a semipurified diet (containing 10% corn oil) containing melatonin so that rats would ingest either 0 ng, 500 ng, 5 mg or 50 mg/day over a period of 3 weeks (n 6 rats/group). At the end of this period, blood samples were obtained around-the-clock via cardiac puncture at six circadian time points. Rats were maintained on a 12L:12D light:dark cycle (lights on 06:00EE18:00 h). Melatonin levels in the 50 or 5 mg/day melatonin groups versus 500 ng/day melatonin and control groups at all time points, P 5 0.05; melatonin levels in the 5 mg/day melatonin group at 04:00 h versus all other time points in the same group, P 5 0.05. Fig. 2 . Effects of dietary melatonin on the growth rate of tissue-isolated hepatoma 7288CTC. Rats were placed on a semi-purified 5% corn oil diet such that they consumed either 0 ng, 500 ng or 5 mg of melatonin/day. Animals began receiving the diets 2 weeks prior to tumor transplantation; diets continued until the end of each growth period. Since the data sets of three independent tumor growth experiments were virtually identical, they were pooled. Therefore, each point represents the mean estimated tumor weight (AESD) of 22EE28 rats/group from the pooled data set. The circadian feeding rhythm and total amount of daily food intake were the same in all groups (data not shown). Tumor growth rates in dietary melatonin groups (500 ng and 5 mg/day) versus controls, P 5 0.05; tumor growth rate in dietary melatonin group (5 mg/day) versus dietary melatonin group (500 ng/day), P 5 0.05.
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groups depicted in Figure 2 that ingested either 0 or 500 ng melatonin/day. However, in animals ingesting 500 ng melatonin/day, peak nocturnal levels of melatonin at 24:00 and 04:00 h, albeit still within the physiological range, were~50% lower than in control rats. In animals ingesting 5 mg of melatonin/ day, circulating melatonin remained consistently at higher levels within the physiological range than in the other two groups throughout the 24-h period with no rhythm being detected. Table III shows that tumor concentrations of melatonin were~10-and 400-fold higher in the 500 ng and 5 mg of melatonin/day groups, respectively, than in the nonsupplemented control group. DoseEEresponse effects of melatonin on LA and total FA uptake, 13-HODE release, DNA content and [ 3 H]thymidine incorporation into DNA and melatonin uptake in hepatoma 7288CTC perfused in situ pineal-intact rats Figure 4A shows the effects of the perfusion of tumors in situ, with whole blood from pinealectomized donor rats containing plasma concentrations of added melatonin ranging from 0 to 1 mM, on tumor LA and total FA uptake and 13-HODE release. There was a significant dose-dependent suppression of tumor LA and total FA uptake and 13-HODE release that reached saturation at 1 nM melatonin. A Dixon plot (54) of the doseEEresponse data for melatonin inhibition of the rate of total FA uptake ( Figure 4A , inset) revealed that the K i calculated for suppression of total FA uptake was 93 pM, which represents the concentration of melatonin that inhibited FA uptake by I P V max . Figure 4B demonstrates a similar dose-dependent suppression of tumor DNA content and [
3 H]thymidine incorporation into DNA by melatonin. As with FA uptake and 13-HODE release, this inhibition of cell proliferation reached saturation at 1 nM melatonin. A-V difference measurements made across tumors perfused with various concentrations of melatonin revealed a tumor melatonin uptake and retention, as a function of supply, that ranged from 20 to 45%; across all melatonin concentrations tested, mean (AESD) tumor melatonin uptake was 31.3 AE 20.4%.
Tumor growth study #2: effects of the dietary intake of melatonin and melatonin receptor antagonist S20928 on the growth, LA uptake, 13-HODE production and melatonin concentration in hepatoma 7288CTC in pineal-intact rats As in our initial experiment, in rats ingesting the 500 ng melatonin/day in the diet, the latency to tumor onset (17 days post-implant) was substantially later (P 5 0.05) than in the control group (10 days post-implant). The tumor growth rate (0.19 AE 0.03 g/day) was much slower than in the control group consuming a melatonin-free diet (0.55 AE 0.06 g/day) ( Figure 5 ). These effects were completely prevented in the group receiving melatonin receptor antagonist S20928 (5 mg/ day) in conjunction with melatonin (500 ng/day). In the group ingesting S20928 alone in the diet, the appearance of tumors (8 AE 0 days post-implant) was sooner than in the controls whereas the tumor growth rate was increased by 65%. While latency to tumor onset (11 days post-implant) was only 24 h later than the controls, the tumor growth rate in the rats ingesting 50 ng of melatonin/day was significantly slower than in the controls ( Figure 5 ). Table II . Effects of dietary melatonin intake (0 and 500 ng or 5 mg/day) on mean (AESD) total FA uptake, FA levels, LA uptake, LA levels, 13-HODE release and melatonin levels in tissue-isolated hepatoma 7288CTC in male rats Biochemical parameters were determined at the end of the growth period for each of the treatment groups in tumor growth study 1 (see Figure 2) . Melatonin was contained in a semi-purified 5% corn oil (CO) diet. Diets were started 2 weeks prior to tumor implantation and were continued until the end of the growth study. Ã P 5 0.05 versus control. ÃÃ P 5 0.05 versus control and melatonin (500 ng/day); n 21EE28 rats (tumors)/group.
[%] represents percent uptake as a function of FA and LA supply. Fig. 3 . Effects of dietary melatonin on mean (AESD) plasma levels of melatonin in pineal-intact male rats bearing tissue-isolated hepatoma 7288CTC (see Figure 2 ). Approximately 1 week prior to the end of each growth period, blood samples were obtained around-the-clock via cardiac puncture at six circadian time points in subgroups of animal (n 6 rats/ group). Rats were maintained on a 12L:12D light:dark cycle (lights on 06:00EE18:00 h). Melatonin levels in the 5 mg/day melatonin group versus the 500 ng/day melatonin and control groups at all time points, P 5 0.05; melatonin levels in the control group at 24:00 and 04:00 h versus all other time points within the same group, P 5 0.05; melatonin levels in the 500 ng/ day melatonin group at 24:00 and 04:00 h versus all other time points within the same group; melatonin levels at 24:00 and 04:00 h on control group versus the 500 ng/day melatonin group, P 5 0.05.
Phytomelatonin suppression of rat hepatoma growth
A-V difference measurements performed across tumors at the end of the growth period in each group shown in Figure 5 indicated that tumor FA and LA uptakes (Table III) , as a percent of supply, were significantly reduced in both the 500 and 50 ng of melatonin/day groups as compared with the control group. In comparison with the 50 ng of melatonin/ day group, tumor total FA and LA uptakes in the 500 ng melatonin/day group were much less. Additionally, the tumor concentrations of total FA and LA in the 500 ng melatonin/day group were significantly reduced as compared with the control group (Table III) . In the 50 ng of melatonin/day group, tumor total FA and LA concentrations were significantly less in the controls. Tumor LA and total FA concentrations in the 500 ng of melatonin/day group were significantly less than in the animals that consumed 50 ng of melatonin/day. The dietary intake of 50 and 500 ng of melatonin/day resulted in tumor 13-HODE release that was significantly lower than in the controls (Table III) . Tumor 13-HODE release was also 35% lower in the rats ingesting 500 versus 50 ng of melatonin/day. Tumor melatonin concentrations in the 50 and 500 ng of Tumors were perfused over a 2 h period with whole blood, from pinealectomized donor rats (no circulating melatonin), to which melatonin was added to achieve final concentrations of either 100, 300 and 600 pM, 1 nM or 1 mM. The inset (A) is a Dixon plot representing reciprocal rates of total FA uptake as a function of the plasma melatonin concentration; K i for suppression of total FA uptake 93 pM. Tumors were perfused with [ 3 H]thymidine incorporation into DNA at 300 pM melatonin versus all other melatonin concentrations, P 5 0.05; at 600 pM to 1 mM melatonin versus 0EE100 pM melatonin, P 5 0.05. DNA content at 600 pM melatonin versus all other melatonin concentrations, P 5 0.05; at 1 nM and 1 mM melatonin versus 0EE300 pM melatonin, P 5 0.05. Table III . Effects of dietary melatonin intake (0, 50 and 500 ng/day) either alone or in combination with melatonin receptor antagonist S20928 (5 mg/day) on mean (AESD) total FA uptake, FA levels, LA uptake, LA levels, 13-HODE release and melatonin levels in tissue-isolated rat hepatoma 7288CTC in male rats Biochemical parameters were determined at the end of the growth period for each of the treatment groups in tumor growth study 2 (see Figure 5 ). Melatonin and/or S20928 were contained in a semi-purified 5% corn oil (CO) diet. Diets were started 2 weeks prior to tumor implantation and were continued until the end of the growth study.
[%] represents percent uptake as a function of FA or LA supply. Ã P 5 0.05 versus control, melatonin S20928. ÃÃ P 5 0.05 versus control, melatonin (500 ng/day). ÃÃÃ P 5 0.05 versus control; n 6 rats (tumors)/group. Fig. 5 . Effects of dietary melatonin, in the presence or absence of melatonin receptor antagonist S20928, on the growth rate of tissue-isolated hepatoma 7288CTC. Rats were placed on a semi-purified 5% corn oil diet such that they consumed either 0, 50 or 500 ng/day of melatonin or 500 ng/day in combination with 5 mg/day of S20928. Animals began receiving diets 2 weeks prior to tumor transplantation and diets continued until the end of each growth period. Each point represents the mean estimated tumor weight (AESD); n 6/group. Tumor growth rates in dietary melatonin groups (50 and 500 ng/day) versus controls and each other, P 5 0.05; tumor growth rate in dietary melatonin group (500 ng/day) versus combined dietary melatonin (500 ng/day) receptor antagonist S20928 (5 mg/day) group, P 5 0.05; tumor growth rate of dietary S20928 group versus controls, P 5 0.05.
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melatonin/day group were increased by 30-and 127-fold, respectively, over concentrations in the control tumors (Table III) . As compared with the 50 ng of melatonin/day group, tumor melatonin concentrations in the 500 ng of melatonin/day group were 4-fold higher. When rats ingested 500 ng melatonin/day in combination with melatonin receptor antagonist S20928, the suppressive effects of melatonin on tumor FA and LA uptake, 13-HODE release, FA and LA concentrations, and melatonin concentrations were completely prevented (Table III) . Interestingly, the ingestion of S20928 by itself caused significant increases in tumor total FA and LA uptakes, FA and LA concentrations and 13-HODE release relative to controls. Although the tumor melatonin concentration was markedly lower in the group ingesting S20928 alone, it was still 4-fold higher than in the control group (Table III) .
Discussion
We confirmed the presence of significant quantities of IR-melatonin reported previously to be present in a wide variety of edible plant species (15EE22). We also documented the presence of significant amounts of IR-melatonin in a number of other edible plants and plant parts that had not been examined previously. All plant species analyzed contained detectable levels of IR-melatonin and several plant foods with the highest levels, including peanuts, walnuts and mustard seed contained 41 ng of melatonin/g of dry tissue weight. Although the amounts of IR-melatonin measured in mustard seed were the highest of all plants analyzed, they were considerably lower than the quantities of melatonin found in these same plant species as reported by other investigators (51, 52) .
Due to its physicochemical properties, melatonin is very difficult to isolate from plant samples due to the presence of melatonin-binding proteins, carbohydrates, lipids, pigments and other unidentified plant components in the plant tissue may have interfered or cross-reacted with the melatonin RIA (19, 20) . Therefore, it is likely that the amounts of IR-melatonin detected here may represent either over-or underestimates of the amounts than would have actually been detected had more sensitive and accurate methods, such as gas chromatographymass spectroscopy, been available (19, 20) . Despite these potential problems in measuring plant melatonin levels with RIA, our results provide additional important evidence that this indoleamine is present in non-trivial concentrations in edible foodstuffs and justifies its designation as`phytomelatonin'.
As alluded to above, pharmacological amounts of melatonin or a melatonin agonist delivered through dietary means has been successfully used in rodent species as a strategy to gradually phase advance central circadian pacemaker activity by reinforcing the endogenous melatonin signal itself as well as to enhance the sensitivity of the circadian timing system to phase-shifting stimuli (29, 30) . These observations indicate that sufficient amounts of melatonin are absorbed and delivered to melatonin-sensitive target tissues to effect changes in circadian physiology. During a 3-week period in the present study, tumor-free, pinealectomized rats consumed a semi-purified diet containing amounts of melatonin that ostensibly would be present in a human phytomelatonin-rich diet. As expected in pinealectomized control rats, the endogenous nocturnal circadian melatonin signal was completely absent. Also, in pinealectomized rats ingesting 5 mg of melatonin/day, à quasi'-physiological nocturnal melatonin signal was reconstituted because the circadian, nocturnal feeding rhythm remained intact in these animals. However, the peak amplitude of the rhythm was phase-delayed by 4 h from the nocturnal peak that is normally generated endogenously by the pineal gland. Following 3 weeks of 50 mg of melatonin/day, melatonin levels were constantly elevated in the nocturnal physiological range throughout the 24-h period. Surprisingly, however, 500 ng of melatonin ingested each day for 3 weeks did not, however, increase blood levels of melatonin above those observed in the pinealectomized controls.
The lack of elevated blood melatonin levels in pinealectomized rats ingesting 500 ng of melatonin/day may, at first, seem counterintuitive; however, there is a plausible explanation for this apparent paradox. It is important to note that the direct, intravenous infusion of 500 ng or more of melatonin/ml plasma/h for 2 h is required to produce a physiological, nocturnal-type' elevation in plasma melatonin concentrations in the rat during the light phase (55) . Infusion with any less than this amount has no effect on plasma melatonin concentrations, which remain at low daytime levels. Therefore, it has been proposed that a significant, nocturnal-type rise in circulating melatonin levels only occurs when the melatonin supply reaches a critical threshold level that exceeds the metabolizing capacity of the liver (55) . Interestingly, it has been estimated that about one-third of the melatonin released by the pineal and/or extra-pineal sources during the dark phase is removed by an unknown mechanism other than hepatic metabolism (56) . In fact,~25% of the melatonin infused into rats accumulates in the gut, which contains over 90% of the whole body melatonin content (57) . Not only is the gut an extra-pineal site of melatonin synthesis, but it also serves as an important`sink' for circulating melatonin (56, 57) . Other tissues that sequester melatonin also include the liver, colon, muscle, kidney, adrenal and pituitary glands. Once melatonin has entered these tissues, it becomes bound to tissue binding proteins (56) . Thus, in the present study, the hepatic extraction, renal clearance and tissue uptake and retention of melatonin may have been greater in pinealectomized than in pineal-intact animals. The fact that peak nocturnal plasma melatonin levels were 5-fold greater and of much longer duration in pineal-intact animals ingesting 5 mg of melatonin/day than in pinealectomized animals ingesting the same amount of the indoleamine supports this notion. If this postulate is correct, it not only could partially explain the low plasma melatonin levels in the 500 ng of melatonin/day group but also the nocturnal physiological melatonin titers in rats consuming microgram quantities of dietary melatonin. Therefore, these plasma melatonin profiles, respresented here as a`snap-shot' in time in relation to dietary melatonin ingestion, may not accurately reflect the true nature of the dynamics of melatonin's distribution to peripheral target tissues.
Dietary melatonin intake, including quantities of the indole that were estimated to be consumed by humans from a phytomelatonin-rich diet, was implemented 2 weeks prior to tumor implantation and continued for several weeks thereafter. This cancer prevention strategy markedly delayed tumor onset and diminished the high rates of hepatoma growth, LA uptake and 13-HODE formation, in a dose-dependent manner. Since 13-HODE is inactivated by UDP-glucuronosyltransferases (UGT) in human liver (58) , it is possible that low levels of these enzymes are expressed in liver tumors. Although speculative, Phytomelatonin suppression of rat hepatoma growth up-regulation of UGTs may represent another mechanism by which 13-HODE levels in rat hepatoma 7288CTC are suppressed by phytomelatonin.
Perfusion of tumors in situ with melatonin for only 2 h at concentrations corresponding to physiological nocturnal plasma levels demonstrated that as little as 93 pM and as much as 1 nM of melatonin were effective in suppressing tumor LA uptake, 13-HODE production and cell proliferation. That these inhibitions required melatonin receptors was strongly indicated by the ability of melatonin receptor antagonist S20928, when co-ingested in the diet, to completely block the effects of melatonin as observed in our previous melatonin perfusion studies (36) . A most interesting discovery was that accelerated rates of tumor growth and LA uptake and metabolism in rats consuming dietary S20928 alone duplicated these same effects induced by pinealectomy or exposure to either constant light or dim light during darkness (36, 59) . These novel results are the first to show, in the area of melatonin/ cancer biology, that interference with the action of the endogenous circadian melatonin signal, at the receptor level, was tantamount to eliminating the melatonin signal itself at its source in the pineal gland.
An unexpected finding was the dose-related accumulation of melatonin in tumor tissue following several weeks of dietary melatonin intake. In fact, tumors perfused in situ for only 2 h with a range of blood plasma melatonin levels encompassing the physiological to pharmacological ranges exhibited a robust 31% uptake and retention of melatonin as a function of supply. Thus, over the course of tumorigenesis, the daily occurrence of tumor melatonin uptake during every 12-h dark period could reasonably explain the substantial accumulation of melatonin within tumor tissue over the course of 3EE6 weeks. Whether cancer cells per se and/or other cell types present in tumors were responsible for melatonin uptake is unknown. However, when MCF-7 human breast cancer cells were exposed to 1 nM melatonin in culture over a 3-day period, cellular melatonin uptake was~50% of the melatonin available in the incubation medium (D.E.Blask, S.T.Wilson and G.M.Vaughan, unpublished results). In this regard, it has been demonstrated that the vast majority of human invasive ductal breast carcinomas not only express MT 1 melatonin receptors (60) but also contain melatonin levels that are 1000-fold higher than nocturnal serum levels (61) . Similarly, high levels of melatonin have been also reported in non-neoplastic breast tissue, including adipose tissue, from both healthy subjects or breast cancer patients (61) . The considerable tumor uptake and retention of melatonin observed in the present investigation indicated that, like the gut and other tissues (56, 57) , tissue-isolated hepatoma 7288CTC was an important repository for melatonin supplied in the diet. Thus, the inability of nocturnal plasma melatonin levels to exceed the physiological range in tumor-bearing rats ingesting melatonin may be ascribed, in part, to rapid tumor sequestration of circulating melatonin. As a result of this process occurring repeatedly over a period of several weeks, it is likely that these steady-state circulating melatonin levels reflect an equilibrium that had been reached between endogenous pineal melatonin production in combination with exogenous melatonin supplementation, on the one hand, and the processes of melatonin metabolism, clearance and uptake/ retention by normal and tumor tissues, on the other.
Normal rat liver cells express melatonin receptors of the MT 2 subtype (62,63), while both MT 1 and MT 2 melatonin receptors are expressed in hepatoma 7288CTC (D.E.Blask, R.T.Dauchy, J.A.Krause, L.A.Sauer and F.Zalatan, unpublished results and ref. 64 ) and mediate melatonin-induced inhibition of FA uptake and 13-HODE production (36) . Although the exact mechanism mediating melatonin's uptake and retention by hepatoma 7288CTC is unclear, it also appears to be consistent with a receptor-mediated phenomenon as revealed by the blockade of tumor melatonin uptake by S20928 (65) . Interestingly, both in rats ingesting S20928 either alone or in combination with dietary melatonin, tumor melatonin levels were 4-fold higher than in control tumors. It appears that while the vast majority of the melatonin available to the tumor tissue is prevented from being taken up by S20928, a much smaller but significant amount of melatonin still gains access to tumor tissue probably owing to melatonin's highly lipophilic nature (8) . For unknown reasons, the dynamics of this process must be different in control tumors in which no receptor blockade is present and only endogenous circulating melatonin levels are available. Although speculative at this time, intratumoral melatonin levels may ultimately reflect a balance between a combination of receptor-mediated uptake and diffusion of melatonin and its intracellular metabolism. Futhermore, the higher tumor FA and melatonin levels in rats ingesting S20928 alone suggests that any endogenous circulating melatonin that has accumulated within tumor tissue, probably via diffusion, may reside in an intracellular compartment that makes it unavailable for interaction with membrane-associated melatonin receptors and thus suppression of FA uptake.
Without direct evidence, a probable explanation for the majority of tumor uptake and retention of melatonin is desensitization and internalization of ligand-occupied melatonin receptors at the cellular level. As mentioned above, diffusion of melatonin into tumor tissue and cells appears to be a much smaller component of the overall mechanism. Once within the cancer cell, melatonin may then become uncoupled from its internalized membrane receptors allowing it to bind to intracellular binding proteins (66) resulting in the increased accumulation of melatonin within tumor tissue. This hypothesis is bolstered by the fact that both MT 1 and MT 2 melatonin receptors have been reported recently to undergo either short-or long-term functional desensitization and internalization in both recombinant systems and native tissues (67EE69). Such a mechanism would also be congruent with the presence of substantial melatonin concentrations in normal and malignant tissues as alluded to above (61) . In the present investigation, melatonin receptor desensitization is indirectly supported by the fact that despite the continued presence of melatonin, the tumor growth rate appeared to accelerate and showed signs of developing refractoriness to melatonin during the later stages of chronic melatonin exposure through the diet. This has obvious clinical implications with respect to the development of melatonin resistance not only in cancer prevention but especially in long-term therapy of human malignancies.
There appears to be a unique interaction taking place at the tumor level between competing environmentally derived oncostatic and oncogenic messages. In the context of circadian organization, the dietary, oncostatic melatonin signal from exogenous sources (i.e. phytomelatonin and/or nutritional supplements) may reinforce the oncostatic melatonin signal generated endogenously by the pineal gland and vice versa. To help maintain the host/cancer balance (70) , this mutually reinforcing circadian, oncostatic information functions to subvert the environmental oncogenic message provided by LA from exogenous dietary sources as well as from endogenous fat stores (37) . Based on the evidence presented here, a strong experimental case can be made that, like other indoleamine phytochemicals such as I3C, phytomelatonin or melatonin contained in nutritional supplements could have a potentially significant impact as a new strategy in human cancer prevention. In this regard, Reiter and colleagues (21) have proposed recently a provocative but cogent argument that melatonin may now have to be considered not only as a hormone, but as an antioxidant nutrient and/or vitamin as well.
